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Abstract
Antibodies directed to citrullinated proteins (e.g. anti-CCP [cyclic citrullinated peptide] antibodies) are 
highly specific for rheumatoid arthritis (RA). These antibodies are produced at the site of inflammation 
in RA, and therefore citrullinated antigens are also expected to be present in the inflamed synovium. 
W e discuss literature showing that the presence of citrullinated proteins in the synovium is not specific 
for RA. The RA-specific antibodies are therefore most likely the result of an abnormal immune response 
that specifically occurs in RA patients. It was recently shown that presence of anti-CCP antibodies 
precedes the onset of clinical symptoms of RA by years. It thus appears that it may take years for initial 
events that cause the generation of anti-CCP antibodies to develop into full-blown disease.
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Introduction
Autoantibodies directed to citrullinated proteins (e.g. anti- 
C C P  [cyclic citrullinated peptide] antibodies) are specific 
serological markers for rheumatoid arthritis (RA). These 
antibodies (for review [1]) are detected in approximately 
80%  of RA patients at a specificity of 98%  [2 -4 ]. Moreover, 
the antibodies are often present in the early stages of the 
disease and are predictive of disease outcom e [5,6]. It 
was recently shown that several RA-associated genetic 
factors may be functionally linked to RA via modulation of 
the production of citrullinated proteins or the antibodies 
directed at them [7]. Taken together, it appears that 
autoreactivity against citrullinated proteins might be 
involved in the disease process in RA.
If such a functional relationship exists, then the antibodies 
and the antigens are expected to be present at the site of 
inflammation. This is clearly the case. Anti-citrullinated 
protein antibodies are produced locally in the synovium, as 
indicated by their 1.4-fold higher proportion of total IgG in 
synovial fluid than in serum (our unpublished data). 
Furthermore, Masson-Bessière and coworkers [8] showed 
that the antibodies comprised a 7.5-fold higher proportion
of IgG in synovial tissue than in serum. These findings 
suggest diffusion of the locally produced antibodies from 
the synovium to the periphery. The presence of anti-CCP 
antibody producing plasma cells in the synovium is 
indicative of an antigen-driven maturation of CCP-specific 
B cells at the site of inflammation in RA [8,9]. It is 
therefore likely that citrullinated proteins are present in the 
inflamed RA synovium. This raises several questions that 
are discussed here.
When does citrullination occur?
Citrullination is the post-translational conversion of 
arginine residues to citrulline residues by peptidylarginine 
deiminase enzymes (PADs; EC 3.5.3.15; for review [10]). 
Five isotypes of PAD have been described in mammals. 
Based on the tissue-specific expression of the enzymes, 
PAD2 and PAD4 are the most relevant to RA because 
they are expressed by certain leucocytes. Normally, PAD 
enzymes are present intracellularly as inactive enzymes
[11]. Calcium ions are required for activation of the PAD 
enzymes, but the intracellular calcium concentration in 
normal cells (10-7 mol/l) is much lower than the threshold 
calcium concentration for PAD activity (approximately
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10- 5 mol/l; our unpublished observations and data from 
Takahara and coworkers [12]). During cell death, however, 
the integrity of the plasma membrane is lost [13,14], 
causing influx of calcium from the extracellular space and 
subsequent activation of intracellular PAD [11 ,15 -18 ]. 
Alternatively, PAD enzymes may leak out of the dying cells, 
become activated (the extracellular calcium concentration is 
approximately 10-3 mol/l, which is sufficient for PAD activity
[12]), and cause citrullination of extracellular proteins.
Which citrullinated proteins are likely to be 
found in the RA synovium?
Many cells in the inflamed synovium have fragmented 
DNA, which is generally considered a sign of apoptosis. 
Nevertheless, these cells lack an apoptosis-specific 
morphology, and the presence of large numbers of 
apoptotic cells in the inflamed synovium is therefore still 
debated [19]. This discrepancy could be explained by the 
possible occurrence of impaired apoptosis. It may be that 
the apoptotic process is halted or that apoptotic cells 
sw itch to necrosis. In both cases, PAD enzymes may 
become activated by raised intracellular calcium levels, as 
probably is the case during the terminal differentiation of 
keratinocytes [20], a process that exhibits many parallels 
w ith halted apoptosis. W e recently found that vimentin is 
citrullinated in dying human macrophages [11]. Because 
m acrophages are abundant in the RA synovium, it is not 
surprising that citrullinated vimentin is present in the 
synovium as well. Indeed, the Sa antigen, which was 
recently identified as citrullinated vimentin [21], can be 
detected in pannus tissue [22]. The Sa antigen is 
specifically targeted by autoantibodies in RA sera (for 
review [23]).
In the inflamed synovium, oxygen metabolism is in 
disequilibrium. This leads on one hand to sites with oxygen 
excess (and subsequent generation of reactive oxygen 
species) and on the other hand to sites of hypoxia, which 
can cause synovial tissue microinfarctions [24,25]. At 
these sites, plaques containing extravascular fibrin are 
commonly found. Masson-Bèssiere and coworkers [26] 
have shown that such deposits contain citrullinated 
proteins. One of these proteins could be identified as 
citrullinated fibrin, which is efficiently recognized by 
autoantibodies present in RA sera.
Although the presence of citrullinated histones in the 
inflamed synovium has not (yet) been reported, it is not 
unlikely that they are present. Citrullination of histones has 
been described ex vivo during calcium-ionophore induced 
apoptosis of granulocytes [17,18]. Large numbers of 
granulocytes are present in the inflamed synovium, 
especially in the synovial fluid. Because granulocytes have 
a lifespan of only about 3 days, they will die in large 
numbers at the site of inflammation, which may trigger 
108 histone citrullination.
In summary, although many different citrullinated proteins 
may be present in the RA synovium, thus far three proteins 
can be considered as candidate autoantigens in RA: 
citrullinated fibrin, citrullinated vimentin and citrullinated 
histones.
Is the occurrence of synovial citrullinated 
proteins a phenomenon specific to RA?
Two possible explanations may be considered for the high 
specificity of autoantibodies directed to citrullinated 
antigens for RA. One possible explanation is that there is 
an RA-specific overexpression of citrullinated antigens in 
the rheumatoid synovium that leads to an immune 
response. Alternatively, presence of citrullinated proteins 
may be a common phenomenon in any inflamed (synovial) 
tissue but RA patients may have an abnormal humoral 
response to them.
The first possibility is supported by the finding of genetic 
polymorphisms in the PAD4 gene [27]. One haplotype of 
PAD4 was associated w ith susceptibility for RA. Although 
it was not shown w hether the PAD4 encoded by the 
susceptible haplotype exhibits an altered enzymatic 
function, it was shown that the RA-susceptible haplotype 
increases PAD4 mRNA stability. In theory, this could result 
in more PAD4 enzyme being produced and subsequently 
lead to increased citrullination of proteins and a higher 
chance of developing anti-CCP antibodies [7,27]. 
Unfortunately, the increased presence of citrullinated 
proteins was not investigated in that study.
Some studies dealing w ith the second possibility have 
recently been published. Masson-Bèssiere and coworkers 
[26] showed that various citrullinated proteins are present 
in the synovial tissue of RA patients. They could be 
detected in the cytoplasm of various mononuclear cells as 
well as in deposits of extravascular fibrin (as described 
above). Although no synovial tissue specimens of non-RA 
patients were initially investigated, a recent fo llow  up of 
that study [28] showed that citrullinated fibrin may also be 
present in synovial tissue of patients w ith other forms of 
joint inflammation. By contrast, Baeten and colleagues 
[29] found citrulline staining in about half of the RA 
patients studied but in none of the control individuals. 
However, the staining pattern they observed was quite 
different from that in the study conducted by Masson- 
Bèssiere and coworkers [26]. The immunohistochemical 
staining was observed in a few, w idely dispersed cells but 
not in extracellular structures. The explanation for this 
discrepancy is probably that the antibody used in the 
study by Baeten and colleagues was developed for the 
detection of free L-citrulline and not for the detection of 
citrullinated proteins [30]. This is illustrated by the fact that 
the staining could be completely abolished by competition 
w ith free L-citrulline [29]. In addition, staining patterns 
similar to the ones described by Baeten and coworkers
Available online http://arthritis-research.com/content/6/3/107
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Schematic representation of the processes that may lead to the citrullination of proteins (left panel) and the immune response to these proteins 
(right panel). As discussed in the text (under the headings ‘When does citrullination occur?' and ‘Which citrullinated proteins are likely to be found 
in the RA synovium?'), peptidylarginine deiminase (PAD)-containing inflammatory cells infiltrate the site of inflammation. At the onset of death of 
these cells, the intracellular calcium concentration is raised, thereby causing activation of PAD enzymes and consequently citrullination of proteins. 
This process is not specific for rheumatoid arthritis (RA; see section entitled ‘Is the occurrence of synovial citrullinated proteins a phenomenon 
specific to RA?'). A combination of impaired clearance of dying cells [42], presence of ‘danger signals' [41] and genetic factors may blend into a 
susceptible environment in which the presence of citrullinated proteins leads to an immune response (see section entitled ‘Why are anti- 
citrullinated protein antibodies so specific for RA?'). As the result of this RA-specific immune response, RA-specific anti-CCP (cyclic citrullinated 
peptide) antibodies are produced.
[29] were observed in a separate study after staining with 
an irrelevant control antibody (rabbit anti-FITC) [31]. 
Based on cellular morphology and colocalization with 
C D 38, it appeared most likely that rheumatoid factor- 
producing plasma cells are detected by this antibody 
rather than citrullinated proteins [31].
Finally, data from our studies, obtained using several types 
of anti-citrullinated protein antibodies, suggest that 
citrullinated proteins can be detected in RA patients but 
also in control individuals (such as patients with 
osteoarthritis or reactive arthritis; our unpublished data, 
and data from Smeets and coworkers [31]). Presence of 
citrullinated antigens in synovial tissue was also not 
associated w ith the presence of anti-CCP autoantibodies 
in serum or synovial fluid. These results thus suggest that 
the presence of citrullinated proteins in the synovium is 
not specific for RA. This conclusion is supported by our 
recent observation that, also in mouse models of arthritis, 
various synovial proteins are citrullinated during 
inflammation [32]. This suggests that citrullination (of 
synovial proteins) is not an RA-specific phenomenon, but 
rather it is an inflammation-related process.
Why are anti-citrullinated protein antibodies 
so specific for RA?
Although arthritis affected mice express citrullinated 
proteins (as discussed above), they do not produce anti- 
citrullinated protein antibodies [32]. This suggests that the 
presence of these antibodies in RA patients is probably 
the result of an abnormal but specific humoral response to 
citrullinated proteins. The anti-citrullinated protein antibody 
subclass distribution (predominantly IgG 1 [1,33]) is
indicative of a T-cell dependent antibody production and 
thus suggests human leukocyte antigen (HLA) involvement
[34]. It has been known for more than 25 years that 
certain HLA haplotypes (e.g. HLA-DR4 [HLA-DRB1*0401 
and *0404 ]) confer a genetic predisposition to RA [35]. It 
was recently shown that citrullinated peptides can be 
bound much more efficiently by DR4 molecules than by 
corresponding non-citrullinated peptides [36]. This 
citrulline-specific interaction might be the basis of a 
citrulline-specific immune response. In experiments with 
HLA-DR4 transgenic mice, proliferation and activation of T 
cells could be induced by citrullinated peptides but not by 
the corresponding arginine-containing peptides [36]. It is 
known that there is a strong correlation between HLA- 
DR4 status and anti-CCP antibody positivity in RA 
patients [37]. The requirement for HLA-DR4 in order to 
develop anti-CCP antibodies is not absolute, but this may 
be attributed to the possibility that other HLA genes (e.g.
DQ) may have a similar preference for certain citrullinated 
peptides [38]. It thus appears that genetic factors such as 
HLA-DR4 are involved in the process that determines 
w hether anti-citrullinated protein antibodies are made.
It may take years for the sparks to ignite the 
fire
It was recently shown that anti-CCP antibodies are 
present very early in the disease, and that their presence 
predicts future progression to RA [5]. Even more so, the 
antibodies can be detected in serum many years before 
onset of the first symptoms of arthritis [39,40]. Although 
the initial events that lead to the anti-citrullinated protein 
immune response are unknown, we believe that in 
principle every trauma or infection that causes death of 109
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PAD-expressing cells may be enough to initiate 
citrullination of proteins. Only in a susceptible individual 
[7] and in a susceptible environment [41] will the 
presence of these citrullinated proteins lead to an immune 
response and to the generation of anti-CCP antibodies. 
A fter this initial spark, some unnoticed symptoms may 
smolder for years until they become more severe, as the 
first clinical symptoms of RA appear. As discussed 
previously [1,7], anti-CCP antibodies may contribute to 
perpetuation of joint inflammation and thereby to 
chronicity and severity of RA.
Conclusion
Recent literature on anti-citrullinated protein antibodies 
and on citrullinated antigens suggests their involvement in 
the disease process of RA. The presence of citrullinated 
antigens is not specific for RA and should probably be 
considered the consequence of the inflammatory process 
(Fig. 1). Based on current knowledge, citrullinated fibrin, 
vimentin and histones are the most likely candidate 
antigens in RA.
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